ArticleGenetics in medicine open2025
Delayed diagnosis and clinical course of alpha-mannosidosis: A retrospective study of 25 patients with varying severity.
Article in Genetics in medicine open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in motor function, quality of life, and clinical manifestations in patients with Alpha-mannosidosis treated with Velmanase Alfa: Data from the French Étoile Alpha registry.Molecular genetics and metabolism reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Alpha-mannosidosis is an ultrarare lysosomal storage disorder characterized by considerable diagnostic delays due to symptom heterogeneity and disease rarity. This study evaluated disease manifestation and clinical course between patients with varying disease severity to identify factors causing delayed diagnosis. Methods: Retrospective chart data were collected from 25 patients diagnosed at age ≥ 16 years categorized as having mild ( Results: Diagnostic delays were longer in patients with mild versus moderate-severe disease (mean [range]: 26.8 [10-46] vs 19.7 [14-30] years). Hearing impairment and learning/communication disability were common first signs in patients with mild and moderate-severe disease, respectively. Learning/communication disability was the most common key diagnostic sign for both groups. Symptoms appeared later in those with mild disease, although disease presentation was similar. Genetic testing confirmed diagnosis in 90% of patients; 64% of patients with mild disease had compound heterozygous variants vs 9% of those with moderate-severe disease. Patients on enzyme replacement therapy had improved or stabilized clinical conditions, indicating treatment importance regardless of age. Conclusion: This study underscores the need for improved diagnostic algorithms to facilitate timely diagnosis and treatment of patients with alpha-mannosidosis. Early suspicion and testing for alpha-mannosidosis in patients with hearing, motor, and learning impairments, along with continued reassessment of adults awaiting confirmed diagnosis are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.